Event Details
January 01, 1993
Description
FDA approval of FC1 Female Condom
Participants (2)
| Name | Type | Mentions | |
|---|---|---|---|
| FDA | person | 0 | View Entity |
| The Female Health Company | organization | 18 | View Entity |
Source Documents (1)
HOUSE_OVERSIGHT_027072.jpg
This document is a proposal from the Female Health Company (FHC) seeking partnership and funding from new donors to supply FC2 female condoms to African nations (specifically Uganda, Kenya, and Zimbabwe) to combat HIV/AIDS. It highlights a funding gap, offers branding opportunities for donors, and cites economic effectiveness studies by Dr. David Holtgrave of Johns Hopkins to justify the investment. The document appears to be part of a larger House Oversight investigation file (HOUSE_OVERSIGHT_027072), likely related to solicitations made to the Epstein Foundation or related entities.
Related Events
Events with shared participants
FDA convened a meeting to analyze data on the drug Praluent, leading to its approval for a larger group of patients than expected.
Date unknown • U.S.
The FDA clearing the drug Praluent for patients with heterozygous familial hypercholesterolemia and certain types of heart disease.
Date unknown
FDA approval of Marinol and Cesamet
1985-01-01 • USA
Marinol approved for treatment of anorexia associated with AIDS
1992-01-01 • USA
Syndros approved by the FDA
2016-01-01 • USA
FDA gave green light for Geron clinical trial.
2009-01-01 • US
FDA accepted GW Pharmaceuticals’ New Drug Application (NDA) for the cannabis-derived drug Epidiolex.
2017-10-01 • USA
FDA published industry guidance on botanical drug development.
2016-12-01 • USA
Previous FDA guidance on botanical drugs issued.
2004-06-01 • USA
FDA convened meeting to analyze drug data.
Date unknown
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein event